Topical use of tacrolimus in the treatment of skin dieseases

Roman Nowicki

ISSN: 1505-8409

Przewodnik Lekarza/Guide for GPs

Current issue Archive About the journal Supplements Abstracting and indexing Contact Instructions for authors

10/2005
vol. 8

Send email

Copy url:

abstract:

Topical use of tacrolimus in the treatment of skin dieseases

Roman Nowicki

Przew Lek 2005; 10; 70-75

Online publish date: 2005/12/22

View full text Get citation

Tacrolimus ointment (Protopic^®;) is the first representative a new class drugs: topical calcineurin inhibitors (TCIs). Its mechanism of action is based on calcineurin inhibition, which results in decreased T-cell activation and inflammatory cytokine release. Tacrolimus ointment is safe and effective for treatment of atopic dermatitis (AD) and others inflammatory diseases in adults and children. The most common adverse events (AEs) associated with its use are a transient burning sensation, pruritus and erythema at the site of application. Unlike topical corticosteroid agents, tacrolimus ointment does not cause a reduction in collagen synthesis or skin thickness. tacrolimus ointment may be safely used for many months on all skin areas, including the face and intertriginous areas. Exposure of the skin to ultraviolet (UV) light should be minimized while using tacrolimus ointment.

keywords:

Topical use of tacrolimus in the treatment of skin dieseases

Roman Nowicki

Protopic®;, topical calcineurin inhibitor, atopic dermatitis, itching, dermatoses

Protopic^®;, topical calcineurin inhibitor, atopic dermatitis, itching, dermatoses